What an exciting first half of 2021, vaccination programs are in full gear, but although progress is noticeable, the world is in a real race between achieving high vaccination rates on the one hand and the emergence of new Sars-Cov2 variants on the other. The corona pandemic continues to hold the world in its grip. The biotech industry, on the other hand, is additionally moved by a new drug, the Alzheimer's drug Aduhelm from Biogen. A few weeks ago, this drug received FDA approval in June of this year. Find out more in a conversation with Dr. Daniel Koller, Head Investment Team, BB Biotech on the occasion of the half-year figures of BB Biotech AG 2021.
«The approval of Biogen’s Alzheimer’s drug is one of the highlights of the second quarter 2021»
Dr. Daniel Koller
Head Investment Management Team BB Biotech
BB Biotech AG uses cookies to improve website usability and ensure the best possible user experience.Use of cookies & disclaimer
